Company Interview / Race Oncology's trial gains speed

Key points

Race Oncology (ASX:RAC) successfully treats first patient in new phase one trial Reformulated drug combines effectively with doxorubicin without complications International trial expansion underway, targeting Hong Kong and South Korea Strong balance sheet supports R&D-focused, lean operations to 2026

Race Oncology (ASX:RAC) achieves a significant milestone with the successful and safe treatment of the first patient in its phase one trial for advanced solid tumours. Daniel Tillett attributes this progress to the reformulation of Race Oncology’s core drug, which now overcomes previous crystallisation challenges and is safely administered alongside the standard anti-cancer drug doxorubicin. Tillett states that no issues have arisen, and the trial marks solid progress for the company, with a strong focus on quickly moving towards completion and expanding patient access.

The trial is broadening its scope internationally, having received human ethics approval for phase one testing at two Hong Kong hospitals, in addition to existing Australian locations and four pending sites in South Korea. Tillett explains this global expansion not only increases patient population diversity but also provides deeper insights into the drug’s effectiveness across varied clinical practices. He highlights that once safety is confirmed, the next step is to prove efficacy in phase two by 2026, acknowledging regulatory requirements to fully test new formulations.

Financially, Race Oncology remains robust, with over $13.5 million cash to support activities through 2026. Tillett emphasises prudent R&D expenditure and a refreshed clinical team driving renewed momentum in clinical development.